Latest BeiGene Ltd. American Depositary Shares (ONC) News on July 12, 2025
Business Wire
17 days ago
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
Business Wire
a month ago
U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications
Investor's Business Daily
a month ago
Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple
Business Wire
a month ago
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
Business Wire
2 months ago
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
MT Newswires
2 months ago
BeiGene Says EU Panel Recommends Tevimbra as Treatment for Nasopharyngeal Cancer
Business Wire
2 months ago
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
Simply Wall St.
2 months ago
BeiGene (NasdaqGS:ONC) Reveals Promising Phase 1 Trial Results Across Multiple Cancer Studies
Business Wire
2 months ago
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference
The Wall Street Journal
2 months ago
Trump's Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks
Simply Wall St.
2 months ago
BeiGene First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St.
2 months ago
Earnings Beat: BeiGene, Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Insider Monkey
2 months ago
BeiGene, Ltd. (ONC): Among Billionaire Lei Zhang’s Stock Picks with Huge Upside Potential
GuruFocus.com
2 months ago
BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ...
MT Newswires
2 months ago
RBC Trims Price Target on BeiGene to $311 From $312, Keeps Outperform Rating
MT Newswires
2 months ago
BeiGene Swings to Q1 Adjusted Earnings, Revenue Increases; 2025 Revenue Outlook Reiterated
Business Wire
2 months ago
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
Business Wire
2 months ago
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
Investor's Business Daily
3 months ago
Will This Cancer Stock Buck Trump's Tariff Onslaught As It Nears Buy Point, Earnings?
Simply Wall St.
3 months ago
BeiGene (NasdaqGS:ONC) Gains 32% In A Quarter Amid Positive EMA Opinion On TEVIMBRA
Business Wire
3 months ago
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
Simply Wall St.
3 months ago
Driven Brands Holdings Among 3 Stocks Priced Below Estimated Fair Value
MT Newswires
4 months ago
Beigene Insider Sold Shares Worth $2,073,826, According to a Recent SEC Filing
MT Newswires
4 months ago
Beigene Insider Sold Shares Worth $24,674,638, According to a Recent SEC Filing
Simply Wall St.
4 months ago
FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction
Pharmaceutical Technology
4 months ago
FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer
MT Newswires
4 months ago
BeiGene Says FDA Approves Tevimbra for Esophageal Cancer First-Line Treatment
MT Newswires
4 months ago
Beigene Insider Sold Shares Worth $331,375, According to a Recent SEC Filing
Simply Wall St.
4 months ago
US$309 - That's What Analysts Think BeiGene, Ltd. (NASDAQ:ONC) Is Worth After These Results
MT Newswires
5 months ago
BeiGene Ltd BeiGene Q4 Net Loss Narrows, Revenue Rises; 2025 Revenue Guidance Set
Business Wire
5 months ago
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Investor's Business Daily
5 months ago
These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50
MT Newswires
5 months ago
BeiGene Insider Sold Shares Worth $12,485,045, According to a Recent SEC Filing
Business Wire
5 months ago
BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
Simply Wall St.
5 months ago
Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:ONC) 41% Undervaluation?
MT Newswires
5 months ago
Beigene Insider Sold Shares Worth $9,424,955, According to a Recent SEC Filing
Clinical Trials Arena
5 months ago
ImmunityBio and BeiGene partner on Phase III trial of NSCLC treatment combo
MT Newswires
5 months ago
ImmunityBio Partners With BeiGene to Conduct Phase 3 Trial of Lung Cancer Combination Therapy
Simply Wall St.
6 months ago
Discover 3 US Stocks Including Microchip Technology That May Be Trading Below Estimated Fair Value
MT Newswires
6 months ago
Beigene Insider Sold Shares Worth $7,370,515, According to a Recent SEC Filing
